Healthtell

The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.

The firm has not disclosed the specific disease the test will address but has determined this space represents the best opportunity for its array technology.

The company, which also raised $14 million in a Series A round, plans to use the proceeds to commercialize panels of tests for autoimmune diseases.

The work found that individuals have steady immunosignatures over time, suggesting longitudinal testing could prove effective for early disease detection.

The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer.

NEW YORK (GenomeWeb) – Having refined its platform and manufacturing process, diagnostics firm HealthTell has now moved into clinical feasibility studies with the aim of launching its first test by the end of next year, CEO Bill Colston told ProteoMonitor this week.

Vermillion has named David Jansen its VP of marketing, a new position at the firm. Jansen joins Vermillion from Myriad Genetics, where he held senior marketing roles for the past seven years.

NEW YORK (GenomeWeb) – In a study published this week in Proceedings of the National Academy of Sciences, researchers at Arizona State University's Biodesign Institute demonstrated the ability o

Biotech firm HealthTell said this week that it has raised $4 million to support development of its immunosignature diagnostic technology.

People In The News

NEW YORK (GenomeWeb News) – The National Institute of General Medical Sciences has appointed Susan Gregurick to direct its Division of Biomedical Technology, Bioinformatics, and Computational Biology.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.